PTAB Trends: Where Does the PTAB Fit in for Life Sciences Companies

PTAB Trends: Where Does the PTAB Fit in for Life Sciences Companies

View Session Speakers

The primary focus of this panel will be a discussion of how post grant proceedings— both post grant review (PGR) and inter partes review (IPR)—  fit within the freedom to operate (FTO) and pre-litigation strategy of life science companies. We will begin the conversation with a discussion of recent trends at the PTAB in the life sciences area, and consider how companies are thinking about bringing or defending against an IPR or PGR in light of recent trends, rules changes made under new PTO leadership, and pending PTAB legislation.

Materials

PTAB Trial Statistics FY 2022 through August 31, 2022

USPTO PTAB Orange Book Update (June 2021)

Why should we encourage generics to challenge pharma patents?

How to Improve IPRs Without Tossing the Baby Out with the Bathwater

Solutions for Inter Partes Review: Restoring patent rights and respect for the presumption of validity

Ships in the Night: Resolving Administrative Conflict between FDA- and Patent-Related Legislation

Supplemental Statement of Paul R. Michel, submitted to the House IP Subcommittee on September 12, 2017

PowerPoint: PTAB Trends

* A Note on Materials: For live, in person programs we apply for MCLE in Virginia, as well as other jurisdictions (see the MCLE tab in the navigation bar above). MCLE regulations require substantive writing on the topic covered during the presentation. The materials provided, often published by IPWatchdog.com authors and contributors, relate to the topic but are not intended to pigeon-hole guest speakers in any way. They are intended to be informative and elucidate the issues that will be discussed, although not necessarily represent the point of view that will be taken by any particular panelist. To date the articles we have selected have always been sufficient to satisfy MCLE authorities.